Tomoya Irie1, Patrick Y Sips1, Shinichi Kai1, Kotaro Kida1, Kohei Ikeda1, Shuichi Hirai1, Kasra Moazzami1, Pawina Jiramongkolchai1, Donald B Bloch1, Paschalis-Thomas Doulias1, Antonis A Armoundas1, Masao Kaneki1, Harry Ischiropoulos1, Evangelia Kranias1, Kenneth D Bloch1, Jonathan S Stamler1, Fumito Ichinose2. 1. From the Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine (T.I., P.Y.S., S.K., K.K., K.I., S.H., P.J., D.B.B., M.K., K.D.B., F.I.), Cardiovascular Research Center, Division of Cardiology, Department of Medicine (K.M., A.A.A., K.D.B.), and Division of Rheumatology Allergy and Immunology, Department of Medicine (D.B.B.), Massachusetts General Hospital and Harvard Medical School, Boston; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.Y.S.); Children's Hospital of Philadelphia Research Institute, Department of Pediatrics and Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania (P.-T.D., H.I.); Department of Research, Shriners Hospitals for Children (M.K.) and Department of Pharmacology (E.K.), University of Cincinnati College of Medicine, OH; and Institute for Transformative Molecular Medicine, Case Western Reserve University, Harrington Discovery Institute University Hospitals, Cleveland, OH (J.S.S.). 2. From the Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine (T.I., P.Y.S., S.K., K.K., K.I., S.H., P.J., D.B.B., M.K., K.D.B., F.I.), Cardiovascular Research Center, Division of Cardiology, Department of Medicine (K.M., A.A.A., K.D.B.), and Division of Rheumatology Allergy and Immunology, Department of Medicine (D.B.B.), Massachusetts General Hospital and Harvard Medical School, Boston; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.Y.S.); Children's Hospital of Philadelphia Research Institute, Department of Pediatrics and Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania (P.-T.D., H.I.); Department of Research, Shriners Hospitals for Children (M.K.) and Department of Pharmacology (E.K.), University of Cincinnati College of Medicine, OH; and Institute for Transformative Molecular Medicine, Case Western Reserve University, Harrington Discovery Institute University Hospitals, Cleveland, OH (J.S.S.). fichinose@mgh.harvard.edu.
Abstract
RATIONALE: The regulation of calcium (Ca(2+)) homeostasis by β-adrenergic receptor (βAR) activation provides the essential underpinnings of sympathetic regulation of myocardial function, as well as a basis for understanding molecular events that result in hypertrophic signaling and heart failure. Sympathetic stimulation of the βAR not only induces protein phosphorylation but also activates nitric oxide-dependent signaling, which modulates cardiac contractility. Nonetheless, the role of nitric oxide in βAR-dependent regulation of Ca(2+) handling has not yet been explicated fully. OBJECTIVE: To elucidate the role of protein S-nitrosylation, a major transducer of nitric oxide bioactivity, on βAR-dependent alterations in cardiomyocyte Ca(2+) handling and hypertrophy. METHODS AND RESULTS: Using transgenic mice to titrate the levels of protein S-nitrosylation, we uncovered major roles for protein S-nitrosylation, in general, and for phospholamban and cardiac troponin C S-nitrosylation, in particular, in βAR-dependent regulation of Ca(2+) homeostasis. Notably, S-nitrosylation of phospholamban consequent upon βAR stimulation is necessary for the inhibitory pentamerization of phospholamban, which activates sarcoplasmic reticulum Ca(2+)-ATPase and increases cytosolic Ca(2+) transients. Coincident S-nitrosylation of cardiac troponin C decreases myocardial sensitivity to Ca(2+). During chronic adrenergic stimulation, global reductions in cellular S-nitrosylation mitigate hypertrophic signaling resulting from Ca(2+) overload. CONCLUSIONS: S-Nitrosylation operates in concert with phosphorylation to regulate many cardiac Ca(2+)-handling proteins, including phospholamban and cardiac troponin C, thereby playing an essential and previously unrecognized role in cardiac Ca(2+) homeostasis. Manipulation of the S-nitrosylation level may prove therapeutic in heart failure.
RATIONALE: The regulation of calcium (Ca(2+)) homeostasis by β-adrenergic receptor (βAR) activation provides the essential underpinnings of sympathetic regulation of myocardial function, as well as a basis for understanding molecular events that result in hypertrophic signaling and heart failure. Sympathetic stimulation of the βAR not only induces protein phosphorylation but also activates nitric oxide-dependent signaling, which modulates cardiac contractility. Nonetheless, the role of nitric oxide in βAR-dependent regulation of Ca(2+) handling has not yet been explicated fully. OBJECTIVE: To elucidate the role of protein S-nitrosylation, a major transducer of nitric oxide bioactivity, on βAR-dependent alterations in cardiomyocyte Ca(2+) handling and hypertrophy. METHODS AND RESULTS: Using transgenic mice to titrate the levels of protein S-nitrosylation, we uncovered major roles for protein S-nitrosylation, in general, and for phospholamban and cardiac troponin C S-nitrosylation, in particular, in βAR-dependent regulation of Ca(2+) homeostasis. Notably, S-nitrosylation of phospholamban consequent upon βAR stimulation is necessary for the inhibitory pentamerization of phospholamban, which activates sarcoplasmic reticulum Ca(2+)-ATPase and increases cytosolic Ca(2+) transients. Coincident S-nitrosylation of cardiac troponin C decreases myocardial sensitivity to Ca(2+). During chronic adrenergic stimulation, global reductions in cellular S-nitrosylation mitigate hypertrophic signaling resulting from Ca(2+) overload. CONCLUSIONS: S-Nitrosylation operates in concert with phosphorylation to regulate many cardiac Ca(2+)-handling proteins, including phospholamban and cardiac troponin C, thereby playing an essential and previously unrecognized role in cardiac Ca(2+) homeostasis. Manipulation of the S-nitrosylation level may prove therapeutic in heart failure.
Authors: N Finley; M B Abbott; E Abusamhadneh; V Gaponenko; W Dong; G Gasmi-Seabrook; J W Howarth; M Rance; R J Solaro; H C Cheung; P R Rosevear Journal: FEBS Lett Date: 1999-06-18 Impact factor: 4.124
Authors: Shakil A Khan; Michel W Skaf; Robert W Harrison; Kwangho Lee; Khalid M Minhas; Anil Kumar; Mike Fradley; Artin A Shoukas; Dan E Berkowitz; Joshua M Hare Journal: Circ Res Date: 2003-05-22 Impact factor: 17.367
Authors: Tslil Ast; Joshua D Meisel; Shachin Patra; Hong Wang; Robert M H Grange; Sharon H Kim; Sarah E Calvo; Lauren L Orefice; Fumiaki Nagashima; Fumito Ichinose; Warren M Zapol; Gary Ruvkun; David P Barondeau; Vamsi K Mootha Journal: Cell Date: 2019-04-25 Impact factor: 41.582
Authors: David M Ryba; Chad M Warren; Chehade N Karam; Robert T Davis; Shamim A K Chowdhury; Manuel G Alvarez; Maximilian McCann; Chong Wee Liew; David F Wieczorek; Peter Varga; R John Solaro; Beata M Wolska Journal: Circ Heart Fail Date: 2019-11-05 Impact factor: 8.790